EWTX Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of -- compared to Edgewise Therapeutics's net margin of 21.93%. Edgewise Therapeutics's return on equity of -- beat Bristol-Myers Squibb's return on equity of 32.01%.

Edgewise Therapeutics has a consensus price target of $42.78, signalling upside risk potential of 188.26%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.84 which suggests that it could grow by 20.75%. Given that Edgewise Therapeutics has higher upside potential than Bristol-Myers Squibb, analysts believe Edgewise Therapeutics is more attractive than Bristol-Myers Squibb.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.408, suggesting its less volatile than the S&P 500 by 59.151%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.09% to investors and pays a quarterly dividend of $0.62 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Edgewise Therapeutics's net income of -$39.7M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 17.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 2.04x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics has a net margin of -- compared to Edgewise Therapeutics's net margin of -886.28%. Edgewise Therapeutics's return on equity of -- beat Cytokinetics's return on equity of --.

Edgewise Therapeutics has a consensus price target of $42.78, signalling upside risk potential of 188.26%. On the other hand Cytokinetics has an analysts' consensus of $77.19 which suggests that it could grow by 90.92%. Given that Edgewise Therapeutics has higher upside potential than Cytokinetics, analysts believe Edgewise Therapeutics is more attractive than Cytokinetics.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.231%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than Cytokinetics quarterly revenues of $16.9M. Edgewise Therapeutics's net income of -$39.7M is higher than Cytokinetics's net income of -$150M. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 244.55x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -- compared to Edgewise Therapeutics's net margin of -14.77%. Edgewise Therapeutics's return on equity of -- beat RxSight's return on equity of -11.86%.

Edgewise Therapeutics has a consensus price target of $42.78, signalling upside risk potential of 188.26%. On the other hand RxSight has an analysts' consensus of $24.36 which suggests that it could grow by 62.97%. Given that Edgewise Therapeutics has higher upside potential than RxSight, analysts believe Edgewise Therapeutics is more attractive than RxSight.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than RxSight quarterly revenues of $40.2M. Edgewise Therapeutics's net income of -$39.7M is lower than RxSight's net income of -$5.9M. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 4.15x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Edgewise Therapeutics's net margin of 24.16%. Edgewise Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

Edgewise Therapeutics has a consensus price target of $42.78, signalling upside risk potential of 188.26%. On the other hand Sarepta Therapeutics has an analysts' consensus of $147.33 which suggests that it could grow by 143.77%. Given that Edgewise Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Sarepta Therapeutics.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Edgewise Therapeutics's net income of -$39.7M is lower than Sarepta Therapeutics's net income of $159M. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 26.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 3.54x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.